Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Zhengyu Yuan"'
Autor:
Jinqian, Liu, Wen, Wang, Changqing, Wang, Li, Zhang, Xueliang, Zhang, Shicong, Liu, Yunhua, Xu, Hailin, Wang, Qing, Dai, Chun, Liu, Xinghai, Wang, Zhengyu, Yuan, Mikhail F, Gordeev
Publikováno v:
ACS medicinal chemistry letters. 13(7)
New oral antibiotic contezolid (CZD) is effective against Gram-positive infections but unsuitable for intravenous (IV) administration due to its modest solubility. To address the medical need for an IV form of CZD, its isoxazol-3-yl phosphoramidate d
Autor:
Jinqian Liu, Wen Wang, Changqing Wang, Li Zhang, Xueliang Zhang, Shicong Liu, Yunhua Xu, Hailin Wang, Qing Dai, Chun Liu, Xinghai Wang, Zhengyu Yuan, Mikhail F. Gordeev
Publikováno v:
ACS Medicinal Chemistry Letters. 13:1030-1035
Publikováno v:
Computers, Materials & Continua. 73:563-576
Autor:
Hong Yuan, Hailan Wu, Yingyuan Zhang, Haihui Huang, Yi Li, Junzhen Wu, Guoying Cao, Jicheng Yu, Beining Guo, Jufang Wu, Zhengyu Yuan, Yuancheng Chen, Wanqiu Yang, Xiaojie Wu, Jing Zhang
Publikováno v:
Antimicrob Agents Chemother
This study aimed to build a population pharmacokinetic (PopPK) model for contezolid tablet (MRX-I) in healthy subjects and adults with complicated skin and soft-tissue infections (cSSTIs) to further evaluate the efficacy and safety of contezolid and
Publikováno v:
Economic Modelling. 120:106184
Publikováno v:
Journal of Antimicrobial Chemotherapy. 77:3210-3211
Publikováno v:
The Journal of antimicrobial chemotherapy. 77(6)
Objectives Contezolid is a novel oxazolidinone antibacterial agent for managing infections caused by aerobic and anaerobic Gram-positive bacteria including methicillin-resistant strains. A Phase III, multicentre, randomized, double-blind, active-cont
Autor:
Liang Li, Mikhail Fedorovich Gordeev, Zhengyu Yuan, Jinqian Liu, Hong Yuan, Chen Li, Dafang Zhong, Jian Meng, Xiaoyan Chen, Jialan Zhou, Cen Xie
Publikováno v:
Drug Metabolism and Disposition. 43:646-659
MRX-I is an analog of linezolid containing a 2,3-dihydropyridin-4-one (DHPO) ring rather than a morpholine ring. Our objectives were to characterize the major metabolic pathways of MRX-I in humans and clarify the mechanism underlying the oxidative ri
Autor:
Mikhail F. Gordeev, Qinglan Guo, Zhengyu Yuan, Baixue Wu, Shicong Liu, Hailin Wang, Wen Wang, Minggui Wang, Xiaogang Xu, Yunhua Xu, Yanqin Huang
Publikováno v:
International Journal of Antimicrobial Agents. 43:418-422
MRX-I is a new oxazolidinone antimicrobial under development. In this study, the potential for development of resistance to MRX-I in Staphylococcus aureus was investigated and key mutations were characterised. Determination of spontaneous resistance
Publikováno v:
Antimicrobial Agents and Chemotherapy. 50:1656-1663
Peptide deformylase (PDF) is an essential enzyme in both gram-negative and gram-positive bacteria. It hydrolyzes formylated N-terminal peptides to generate free N-terminal peptides during the process of protein maturation. Inhibition of this enzyme r